



NDA 022253/S-042  
NDA 022254/S-033  
NDA 022255/S-024

**SUPPLEMENT APPROVAL**

UCB, Inc.  
Attention: Laila El-Asmar, Ph.D.  
Associate Director, Regulatory Affairs  
1950 Lake Park Drive  
Building 2100  
Smyrna, GA 30080

Dear Dr. El-Asmar:

Please refer to your Supplemental New Drug Applications (sNDAs) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

Application	Product Name	Submitted & received on:
NDA 022253/S-042	Vimpat (lacosamide) tablets	May 11, 2018
NDA 022254/S-033	Vimpat (lacosamide) injection	
NDA 022255/S-024	Vimpat (lacosamide) oral solution	

These Prior Approval supplemental new drug applications provide for revisions to the Warnings and Precautions (Section 5.3—Cardiac Rhythm and Conduction Abnormalities), Dosage and Administration, Drug Interactions, Overdosage, and Patient Counseling Information sections of the Prescribing Information, as well as the Medication Guide, to reflect new information related to the risk for serious cardiac events (e.g., cardiac arrest, asystole, atrioventricular block, and ventricular arrhythmias). In addition, these Prior Approval supplemental new drug applications provide for revisions to Section 5.6 (Warnings and Precautions; Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]/Multi-Organ Hypersensitivity) to reflect that DRESS has been reported in patients treated with Vimpat and to provide greater consistency with the language related to the risk for DRESS in other antiepileptic drug labels.

**APPROVAL & LABELING**

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 022253/S-042  
NDA 022254/S-033  
NDA 022255/S-024  
Page 3

If you have any questions, call Stephanie N. Parncutt, M.H.A., Senior Regulatory Health Project Manager, at (301) 796-4098 or email [Stephanie.Parncutt@fda.hhs.gov](mailto:Stephanie.Parncutt@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Alice Hughes, M.D.  
Deputy Director for Safety  
Division of Neurology Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURE(S):

Content of Labeling  
Prescribing Information  
Medication Guide

NDA 022253/S-042  
NDA 022254/S-033  
NDA 022255/S-024  
Page 4

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

ALICE HUGHES  
11/11/2018